Terbinafine-induced subacute cutaneous lupus erythematosus.
BACKGROUND
Recently, the induction of subacute cutaneous lupus erythematosus (SCLE) and exacerbation of systemic lupus erythematosus by terbinafine have been reported.


OBJECTIVE
We describe 4 cases of SCLE, one associated with chilblain lupus, which occurred during therapy with oral terbinafine for onychomycosis.


METHODS
Of 21 consecutive patients with SCLE attending the outpatient dermatology department at Muenster University clinic during a 1-year period, 4 patients with terbinafine-induced SCLE were seen. Patients were examined fully and photographed; histologic findings as well as serologic and follow-up data were evaluated.


RESULTS
In addition to high titers of antinuclear antibodies (ANA) with a homogeneous pattern, anti-Ro(SS-A) antibodies were present; in 3 of 4 women, anti-La(SS-B) antibodies were also found. All patients had anti-histone antibodies as in drug-induced lupus and showed the characteristic genetic association of SCLE with the HLA-B8,DR3 haplotype; moreover, in 2 cases, HLA-DR2 was also present. After discontinuation of terbinafine, ANA titers decreased; anti-histone antibodies also became undetectable within 4(1/2) months in 3 patients concomitant with subsidence of the SCLE eruption in all patients.


CONCLUSIONS
Terbinafine is a drug that appears to infrequently induce SCLE with high titers of ANAs and anti-histone antibodies in genetically susceptible persons.
Bonsmann
G
G
Department of Dermatology, University of Münster, Germany. bonsmag@uni-muenster.de
Schiller
M
M
Luger
T A
TA
Ständer
S
S
D000284:Administration, Oral; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006657:Histones / Q000276:immunology; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects* / Q000627:therapeutic use; D014009:Onychomycosis / Q000188:drug therapy; D000077291:Terbinafine
D000974:Antibodies, Antinuclear; D000935:Antifungal Agents; D006657:Histones; D009281:Naphthalenes; D000077291:Terbinafine